Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Herbal formula aims to stop bladder Cancer's return

NCT ID NCT07728474

Disease control Sponsor: LifeBiotic Medical Research Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This trial tests whether an oral herbal supplement called LCS103 can help prevent non-muscle invasive bladder cancer from recurring after surgery. Sixty adults who have had their bladder tumors completely removed will take either LCS103 plus standard care or standard care alone for one year. The study will track safety and how well the supplement works at keeping the cancer away.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an oral herbal formula called LCS103
What this could lead to
If it works, this could offer a simple, non-invasive way to reduce the risk of bladder cancer returning after surgery.
What could go wrong
This is an early-phase trial with only 60 participants, so results may not apply widely. The herbal formula may cause side effects or fail to prevent recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women aged ≥ 18 years. * Non-muscle invasive urothelial carcinoma, histologically confirmed by TURBT procedure within 3 months before enrollment. * Complete resection of bladder tumor in recent TURBT. Exclusion Criteria: * Inability to provide informed consent. * Inability to swallow tablets (esophageal stricture, feeding through gastrostomy). * Ineligibility for SOC therapy such as BCG instillations (where appropriate). * Upper tract urothelial carcinoma within the past 2 years. * Any malignancy other than NMIBC, active or systemically treated within the past 2 years (not including localized cutaneous basal cell or squamous cell carcinoma). * Estimated life expectancy \< 5 years. * Pregnant women, and women planning future pregnancy or wishing to preserve fertility. * Investigator evaluation of a physical or mental condition limiting a patient's ability to participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-muscle invasive bladder cancer (nmibc) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-muscle invasive bladder cancer (nmibc)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Rambam Health Care Campus, Urology Department

    RECRUITING

    Haifa, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.